Colombo C, Battezzati P M
Department of Pediatrics, University of Sassari, Italy.
Eur J Gastroenterol Hepatol. 1996 Aug;8(8):748-54.
Cystic fibrosis is the most common, potentially lethal genetic defect in the Caucasian population. During recent years it has been increasingly associated with a number of hepatic and biliary abnormalities, of which chronic cholestatic liver disease is by far the most relevant. Plugging of intrahepatic bile ducts with inspissated secretions is thought to play a major role in the pathogenesis. Attempts have been made to provide uniform criteria to identify patients with early, possibly reversible, hepatic lesions, as well as to assess severity of liver disease. It has been estimated that bout 13% of cystic fibrosis patients present serum liver enzyme abnormalities, but prevalence of liver involvement is likely to be higher. Due to decreasing mortality from extrahepatic causes in cystic fibrosis and to the widespread use of laboratory tests and ultrasound examination, patients with minor degree of liver involvement will be increasingly represented in future. Oral bile acid therapy is promising, but its long-term benefits in terms of survival and prevention of major complications of liver cirrhosis remain to be established. Liver transplantation is the only potentially curative treatment for patients with advanced stage liver disease and mild pulmonary involvement.
囊性纤维化是白种人群中最常见的、潜在致命的基因缺陷病。近年来,它与许多肝脏和胆道异常越来越相关,其中慢性胆汁淤积性肝病是迄今为止最相关的。肝内胆管被浓缩分泌物堵塞被认为在发病机制中起主要作用。人们已尝试提供统一标准来识别有早期、可能可逆的肝脏病变的患者,以及评估肝脏疾病的严重程度。据估计,约13%的囊性纤维化患者存在血清肝酶异常,但肝脏受累的患病率可能更高。由于囊性纤维化患者肝外原因导致的死亡率下降,以及实验室检查和超声检查的广泛应用,未来肝脏受累程度较轻的患者将越来越多。口服胆汁酸治疗前景广阔,但其在生存和预防肝硬化主要并发症方面的长期益处仍有待确定。肝移植是晚期肝病且肺部受累较轻患者唯一可能治愈的治疗方法。